LQDA · Insider Trading
Liquidia Corporation Common Stock
Every open-market purchase and sale reported by LQDA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-13 | Roger Jeffs | Chief Executive Officer | MIXED | −4,578 | −$932.55K |
| 2026-10-13 | Dana Boyle | Chief Accounting Officer | MIXED | −2,714 | −$167.80K |
| 2026-10-13 | Rajeev Saggar | Chief Medical Officer | MIXED | −1,202 | −$262.53K |
| 2026-10-13 | Sarah Krepp | Chief Human Resource Officer | MIXED | −2,067 | −$149.38K |
| 2026-10-13 | Jason Adair | Chief Business Officer | MIXED | +2,947 | −$207.93K |
| 2026-10-13 | Michael Kaseta | CFO and COO | MIXED | −6,061 | −$539.35K |
| 2026-10-13 | Sanjeev Khindri | Chief Development Officer | Sell | −1,101 | −$31.36K |
| 2026-10-13 | Russell Schundler | General Counsel | MIXED | −3,525 | −$389.95K |
| 2026-10-13 | Scott Moomaw | Chief Commercial Officer | MIXED | −1,397 | −$252.42K |
| 2026-10-07 | Stephen M Bloch | Director | Sell | −235,477 | −$6.39M |
| 2026-09-15 | Raman Singh | Director | MIXED | — | −$1.02M |
| 2026-09-03 | Sarah Krepp | Chief Human Resource Officer | Sell | −274 | −$18.57K |
| 2026-08-25 | Jason Adair | Chief Business Officer | MIXED | −41,832 | −$4.74M |
| 2026-08-21 | Katherine Rielly-Gauvin | Director | MIXED | — | −$3.95M |
| 2026-08-19 | Rajeev Saggar | Chief Medical Officer | MIXED | −29,534 | −$5.79M |
| 2026-07-29 | Dana Boyle | Chief Accounting Officer | Sell | −1,600 | −$140.05K |
| 2026-07-29 | Jason Adair | Chief Business Officer | Sell | −688 | −$60.22K |
| 2026-07-24 | Stephen M Bloch | Director | Sell | −200,000 | −$17.79M |
| 2026-07-22 | Stephen M Bloch | Director | Sell | −78,596 | −$6.29M |
| 2026-07-14 | Scott Moomaw | Chief Commercial Officer | MIXED | −2,073 | −$682.14K |
| 2026-07-14 | Sanjeev Khindri | Chief Development Officer | Sell | −1,185 | −$84.74K |
| 2026-07-14 | Roger Jeffs | Chief Executive Officer | MIXED | −7,082 | −$2.52M |
| 2026-07-14 | Michael Kaseta | CFO and COO | MIXED | −7,551 | −$1.46M |
| 2026-07-14 | Russell Schundler | General Counsel | MIXED | −4,570 | −$1.05M |
| 2026-07-14 | Rajeev Saggar | Chief Medical Officer | MIXED | −1,908 | −$709.82K |
| 2026-07-14 | Jason Adair | Chief Business Officer | MIXED | +2,388 | −$562.29K |
| 2026-07-14 | Dana Boyle | Chief Accounting Officer | MIXED | −5,823 | −$643.74K |
| 2026-07-14 | Sarah Krepp | Chief Human Resource Officer | MIXED | −4,685 | −$562.36K |
| 2026-07-08 | Stephen M Bloch | Director | Sell | −75,000 | −$6.05M |
| 2026-07-06 | Stephen M Bloch | Director | Sell | −25,000 | −$1.99M |
| 2026-06-24 | Stephen M Bloch | Director | Sell | −100,000 | −$7.57M |
| 2026-06-18 | Damian deGoa | Director | A | +5,882 | — |
| 2026-06-18 | Arthur S Kirsch | Director | A | +5,882 | — |
| 2026-06-18 | David Edward Johnson | Director | A | +11,764 | — |
| 2026-06-18 | Joanna Horobin | Director | A | +5,882 | — |
| 2026-06-18 | Stephen M Bloch | Director | A | +5,882 | — |
| 2026-06-18 | Raman Singh | Director | A | +5,882 | — |
| 2026-06-18 | Katherine Rielly-Gauvin | Director | A | +5,882 | — |
| 2026-06-18 | Paul B Manning | Director | A | +5,882 | — |
| 2026-06-16 | Stephen M Bloch | Director | Sell | −196,111 | −$14.01M |
| 2026-06-15 | Sarah Krepp | Chief Human Resource Officer | Sell | −24,880 | −$1.75M |
| 2026-06-12 | Stephen M Bloch | Director | Sell | −388,223 | −$26.63M |
| 2026-06-10 | Sanjeev Khindri | Chief Development Officer | Sell | −4,134 | −$270.61K |
| 2026-06-10 | Stephen M Bloch | Director | Sell | −220,835 | −$14.27M |
| 2026-06-08 | Paul B Manning | Director | Sell | −200,000 | −$12.78M |
| 2026-06-08 | Stephen M Bloch | Director | Sell | −84,800 | −$5.51M |
| 2026-06-03 | Arthur S Kirsch | Director | Sell | −30,000 | −$1.73M |
| 2026-06-03 | Sarah Krepp | Chief Human Resource Officer | Sell | −276 | −$16.80K |
| 2026-05-28 | Roger Jeffs | Chief Executive Officer | Sell | −6,428 | −$399.71K |
| 2026-05-26 | Roger Jeffs | Chief Executive Officer | Sell | −75,000 | −$4.58M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David Edward Johnson | Director | 8,163,229 | $280.41M |
| Roger Jeffs | Chief Executive Officer | 1,190,854 | $40.91M |
| Paul B Manning | Director | 911,139 | $31.30M |
| Russell Schundler | General Counsel | 617,341 | $21.21M |
| Michael Kaseta | CFO and COO | 340,148 | $11.68M |
| Scott Moomaw | Chief Commercial Officer | 181,487 | $6.23M |
| Jason Adair | Chief Business Officer | 178,916 | $6.15M |
| Dana Boyle | Chief Accounting Officer | 165,609 | $5.69M |
| Rajeev Saggar | Chief Medical Officer | 150,685 | $5.18M |
| Sarah Krepp | Chief Human Resource Officer | 120,486 | $4.14M |
| Stephen M Bloch | Director | 104,570 | $3.59M |
| Damian deGoa | Director | 92,353 | $3.17M |
| Sanjeev Khindri | Chief Development Officer | 64,846 | $2.23M |
| Arthur S Kirsch | Director | 46,637 | $1.60M |
| Katherine Rielly-Gauvin | Director | 44,637 | $1.53M |
| Raman Singh | Director | 44,637 | $1.53M |
| Joanna Horobin | Director | 39,637 | $1.36M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LQDA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.